Joint Discovery of Promising Biotech Startups

SK Biopharm is partnering with Seoul Bio Hub to discover domestic biotech startups. The company plans to accelerate its open collaboration model based on its experience in global new drug development.


On February 2, SK Biopharm announced the official launch of the 'Open Innovation Program' in collaboration with Seoul Bio Hub, Seoul's bio and medical startup platform. The program aims to identify early-stage biotech companies with promising technologies, particularly in the central nervous system and oncology fields, and promote joint research and commercialization.

Promotional image for the '2026 Seoul Bio Hub' program. SK Biopharm

Promotional image for the '2026 Seoul Bio Hub' program. SK Biopharm

View original image

This program targets pharmaceutical and biotech startups established less than eight years ago, as well as aspiring entrepreneurs. Eligible companies must possess technologies that align with SK Biopharm’s research needs in areas such as the central nervous system, oncology, artificial intelligence, aging, and non-cosmetic fields. Two companies will be selected through a screening process.


The selected companies will be given opportunities for technology validation and joint research throughout the entire cycle of global new drug development. They will also receive R&D consulting, workspace at Seoul Bio Hub, and rental support. A separate agreement will be signed with SK Biopharm.


SK Biopharm has accumulated full-cycle experience from R&D to commercialization by independently developing cenobamate, an epilepsy treatment, and launching it in the US market. The focus of this program is to share such experience with startups and generate tangible collaborative outcomes.


The company has established an Open Innovation Center this year and is pursuing a strategy that combines research on new modalities with external collaborations. The collaboration with Seoul Bio Hub marks the center’s first partnership since its launch.


Kim Hyunwoo, Head of Seoul Bio Hub, stated, "This is a collaboration with a company that has successfully launched a self-developed new drug in the US market. It will provide startups with a valuable opportunity to directly experience the global new drug development process."


Lee Donghoon, CEO of SK Biopharm, said, "We will share the experience we have accumulated in new drug development and commercialization with startups and hope this leads to results with global competitiveness."



Applications and detailed information about the program can be found on the Seoul Bio Hub website.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing